What are long-acting beta agonists primarily used for in respiratory therapy?

Long-acting beta agonists (LABAs) are primarily utilized in respiratory therapy to provide bronchodilation. LABAs work by stimulating beta-2 adrenergic receptors in the smooth muscles of the airways, leading to relaxation and expansion of these muscles. This action helps to improve airflow in conditions such as asthma and chronic obstructive pulmonary disease (COPD).

The effect of LABAs typically lasts for 12 hours or more, which makes them particularly useful for long-term management of airway obstruction and for preventing nighttime symptoms. They are often used in conjunction with inhaled corticosteroids for a more comprehensive treatment approach that addresses both bronchoconstriction and underlying inflammation.

The other options, such as reducing inflammation, suppressing cough, and improving lung compliance, do not accurately describe the primary function of LABAs. Inhaled corticosteroids are responsible for reducing inflammation. Cough suppressants are a separate class of medication, and improving lung compliance generally pertains to conditions like pulmonary fibrosis or other restrictive lung diseases. Therefore, the role of LABAs is specifically centered on facilitating bronchodilation, making their use crucial for effective respiratory therapy management.